Email Not Verified

Action Required

Please go to your profile settings and make sure your email is verified before applying for account verification.

Please refer to the documentation here.

Confirm Account Verification

Final Step

Please make sure you have filled in all the required details.

We need these details to verify your account. Once you click Yes, we will send an account activation request to our team.

Please refer to the documentation here.
Back to Top
Go Back
Journal Photo for Journal of Alzheimers Disease & Parkinsonism
Peer reviewed only Open Access

Journal of Alzheimers Disease & Parkinsonism (JADP)

Publisher : OMICS International Pvt Ltd
Alzheimer’s Disease Parkinsonism Neurodegenerative Disorders
e-ISSN 2161-0460
Issue Frequency Bi-Monthly
Impact Factor 2.04
Est. Year 2011
Mobile 16506189889
DOI YES
Language English
APC YES
Impact Factor Assignee Google Scholar
Email submissions@omicsonline.com

Journal Descriptions

Journal of Alzheimers Disease & Parkinsonism aims to bridge knowledge gaps separating traditional fields of dementia research. Alzheimer's Journal publishes peer reviewed articles with highest impact factor offers open access option to meet the needs of authors and maximize article visibility. Advanced parkinson treatment, advances in alzheimers therapy, alzheimers medicine, alzheimers products & market analysis, alzheimers symptoms, degenerative disorders, diagnostic alzheimer, parkinson, parkinsonism diagnosis, parkinsonism gene therapy, parkinsonism stages and treatment.

Journal of Alzheimers Disease & Parkinsonism (JADP) is :-

  • International, Peer-Reviewed, Open Access, Refereed, Alzheimer’s Disease, Parkinsonism, Neurodegenerative Disorders, Neurology, Dementia Research, Neuropharmacology, Neurogenetics, Neuroscience , Online , Bi-Monthly Journal

  • UGC Approved, ISSN Approved: P-ISSN E-ISSN: 2161-0460, Established: 2011, Impact Factor: 2.04
  • Provides Crossref DOI
  • Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE

Publications of JADP

Sherif Salah May, 2016
Developed a novel DNA polymerase–based therapeutic strategy for multiple sclerosis with potential immunomodulatory and disease-modifying effects.